$CPIX News

Cumberland Pharmaceuticals: The FDA's Phase 3 Question Is Hard To Ignore

Cumberland Pharmaceuticals Begins Rolling FDA NDA for Dyscorban in Duchenne Cardiomyopathy

CUMBERLAND PHARMACEUTICALS ANNOUNCES PLANS TO FILE NEW DRUG APPLICATION FOR IFETROBAN DMD PROGRAM

Cumberland Pharmaceuticals Inc. (CPIX) Discusses Duchenne Cardiomyopathy NDA Submission and Product Development Strategy Prepared Remarks Transcript

Cumberland Pharmaceuticals Intends To File New Drug Application To FDA For Ifetroban To Treat Cardiomyopathy Associated With Duchenne Muscular Dystrophy

Cumberland Pharmaceuticals stock tumbles on trial results

Cumberland Pharmaceuticals Announces ASSIST-SSc Trial Top-Line Results

Cumberland Pharmaceuticals Announces Data From Its Phase 2 ASSIST-SSc Study Of Oral Ifetroban For Patients With Systemic Sclerosis; Gastrointestinal Adverse Events Were More Frequent In Ifetroban Group Than Placebo; Majority Of Patients Demonstrated Limited Disease Progression, Which Reduced Ability To Track Treatment Difference

CUMBERLAND PHARMACEUTICALS PROVIDES UPDATED WEBCAST REGISTRATION LINK FOR IFETROBAN DMD PROGRAM CALL

CUMBERLAND PHARMACEUTICALS ANNOUNCES NATIONAL CALL TO PRESENT AN UPDATE ON ITS IFETROBAN DMD PROGRAM

Cumberland Pharmaceuticals: Pivot Into Drug Development Creates Risk, Opportunity

Cumberland Pharmaceuticals Inc (CPIX) (Q2 2026) Earnings Call Highlights: Strategic ...

Cumberland Pharmaceuticals Q2 Earnings Call Highlights

CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS

Cumberland Pharmaceuticals Inc. (CPIX) Q2 2026 Earnings Call Transcript

Cumberland Q2 Adj. EPS $(0.20) Down From $(0.13) YoY, Sales $166.458K Down From $380.797K YoY

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS

/C O R R E C T I O N -- Cumberland Pharmaceuticals Inc./

Cumberland Pharmaceuticals Declares $1.50/Share Special Dividend

Apotex Completes Previously Announced Strategic Transaction with Cumberland Pharmaceuticals